Q3 2025 Protalix Biotherapeutics Inc Earnings Call Transcript
Key Points
- Protalix BioTherapeutics Inc (PLX) reported a 24% increase in total revenues for the first nine months of 2025 compared to the same period last year.
- The company has a strong cash position with $29.4 million in cash and cash equivalents, sufficient to meet capital needs for at least 12 months.
- Protalix BioTherapeutics Inc (PLX) is advancing its PRX 115 candidate for uncontrolled gout, with preparations for a phase 2 clinical trial well underway.
- The company maintains a focus on financial discipline, achieving positive quarterly net income.
- Protalix BioTherapeutics Inc (PLX) continues to strengthen its commercial foundation with the enzyme replacement therapy, El Fabio, which remains available to patients in the EU.
- Total revenues for the third quarter of 2025 decreased by 1% compared to the same period in 2024.
- The company faces regulatory challenges, as the Committee of Medicinal Products for Human Use (CHMP) issued a negative opinion on the proposed every 4 weeks dose regimen for El Fabio in Europe.
- Research and development expenses increased by 58% for the nine months ended September 30, 2025, reflecting higher costs associated with the PRX 115 clinical trial preparations.
- Protalix BioTherapeutics Inc (PLX) recorded a net loss of $1.1 million for the nine-month period ended September 30, 2025.
- There is uncertainty regarding the predictability of royalty-based revenue recognition related to El Fabio sales, which may impact financial reporting.
Greetings and welcome to the Protalix Biotherapeutics 3rd quarter financial and business results conference call. At this time, all participants are on a listen-only.
A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Moyer, Investor relations.
Thank you, sir. You may begin.
Thank you.
One moment please.
Thank you, operator, and welcome to the Protalix Biotherapeutics.
Third quarter 2025.
Financial results and business update conference call.
With me today are Jor Bashan, CEO of Palix.
And Gilad Mamla.
Senior Vice President and Chief Financial Officer. A press release announcing the financial results for the quarter and corporate updates was issued this morning and is available now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
